Triple Negative Breast Cancer

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS trial_result · 2024-03-12
Clinical Trial Update: Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer [Phase 2]
Phase 2 trial update for trilaciclib in early-stage triple-negative breast cancer has completed with results posted.